Nintedanib esylate
|
|
Nintedanib esylate 속성
- 녹는점
- >233°C (dec.)
- 저장 조건
- -20°C Freezer
- 용해도
- DMSO(약간 용해됨), 메탄올(약간 용해됨)
- 물리적 상태
- 노란색 고체.
- 색상
- 밝은 노란색에서 노란색까지
안전
- 위험 및 안전 성명
- 위험 및 사전주의 사항 (GHS)
Nintedanib esylate C화학적 특성, 용도, 생산
개요
Nintedanib esylate is a potent, oral triple angiokinase inhibitor developed by Boehringer Ingelheim that targets proangiogenic and pro-fibrotic pathways mediated by the vascular endothelial growth factor receptor, fibroblast growth factor receptor and plateletderived growth factor receptor families, as well as Src and Flt-3 kinases. It was approved for the treatment of idiopathic pulmonary fibrosis (IPF), a condition in which the lungs become progressively scarred over time, by the US FDA in October 2014 and by the EMA in January 2015. The FDA granted nintedanib esylate fast-track, priority review, orphan product, and breakthrough designations. The drug was also approved by the EMA in November 2014 for treatment of non-small cell lung cancer in combination with docetaxel after first-line chemotherapy.용도
Nintedanib Esylate is the salt form of Nintedanib, which is angiokinase inhibitor and is used in the treatment of idiopathic pulmonary fibrosis. Also inhibits the process blood vessel formation which may be used to assist in cancer therapy.정의
ChEBI: An organosulfonate salt obtained by combining nintedanib with one molar equivalent of ethanesulfonic acid. A kinase inhibitor used for the treatment of idiopathic pulmonary fibrosis and cancer.Properties and Applications
Nintedanib esylate (NE) is used in the treatment of idiopathic pulmonary fibrosis (IPF) and in diverse cancers, including nonsmall cell lung cancer (NSCLC). NE has a pH-dependent solubility profile with low aqueous solubility under neutral pH and increased solubility at acidic pH. The oral bioavailability of NE is 4.7% because it is a P-gp substrate and also undergoes first-pass metabolism in the liver by esterases. However, the administration of NE along with food increases the area under the curve (AUC) and maximum concentration (Cmax) when the drug is taken with food; hence, it has a positive food effect[1].Nintedanib esylate 준비 용품 및 원자재
원자재
Ethanesulfonic acid
Nintedanib
메틸2-옥소인돌-6-카르복실레이트
1-(2-클로로아세틸)-2-옥소-2,3-디히드로-1H-인돌-6-카르복실산메틸에스테르
메틸1-아세틸-2-옥소인돌린-6-카르복실레이트
2-클로로-N-메틸-N-(4-니트로페닐)아세트아미드
(3E)-1-Acetyl-3-(ethoxyphenylmethylene)-2,3-dihydro-2-oxo-1H-indole-6-carboxylic Acid Methyl Ester
준비 용품
Nintedanib esylate 공급 업체
글로벌( 307)공급 업체
공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
---|---|---|---|---|---|
Hebei Yanxi Chemical Co., Ltd. | +86-17531190177; +8617531190177 |
peter@yan-xi.com | China | 6011 | 58 |
Shanghai Daken Advanced Materials Co.,Ltd | +86-371-66670886 |
info@dakenam.com | China | 16216 | 58 |
Beijing Cooperate Pharmaceutical Co.,Ltd | 010-60279497 |
sales01@cooperate-pharm.com | CHINA | 1811 | 55 |
Shanghai Bojing Chemical Co.,Ltd. | +86-86-02137122233 +8613795318958 |
bj1@bj-chem.com | China | 299 | 55 |
Henan Tianfu Chemical Co.,Ltd. | +86-0371-55170693 +86-19937530512 |
info@tianfuchem.com | China | 21670 | 55 |
Hangzhou FandaChem Co.,Ltd. | 008657128800458; +8615858145714 |
fandachem@gmail.com | China | 9337 | 55 |
Nanjing ChemLin Chemical Industry Co., Ltd. | 025-83697070 |
product@chemlin.com.cn | CHINA | 3012 | 60 |
Shanghai Yingrui Biopharma Co., Ltd. | +86-21-33585366 - 03@ |
sales03@shyrchem.com | CHINA | 738 | 60 |
ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 |
ivan@atkchemical.com | China | 32760 | 60 |
Lianyungang happen teng technology co., LTD | 15950718863 |
wang666xt@163.com | CHINA | 295 | 58 |
Nintedanib esylate 관련 검색:
N-메틸-4-나이트로아닐린
Nintedanib
Methyl 2-oxoindole-6-carboxylate
Propylparaben
(3E)-2,3-Dihydro-3-(methoxyphenylmethylene)-2-oxo-1H-indole-6-carboxylic acid methyl ester
BIBF-1120
2-CHLORO-N-METHYL-N-(4-NITROPHENYL)ACETAMIDE
2-broMo-N-Methyl-N-(4-nitrophenyl)acetaMide
N-(4-aminophenyl)-N-methyl-2-(4-methylpiperazin-1-yl)acetamide
N-methyl-2-(4-methylpiperazin-1-yl)-N-(4-nitrophenyl)acetamide
1,3-DiMethyl 2-[4-(Methoxycarbonyl)-2-nitrophenyl]propanedioate
Ruxolitinib phosphate
Alectinib Hydrochloride
PLX4032
Olaparib
Crizotinib
Afatinib (BIBW 2992)
PLERIXAFOR